&nbsp;

Updated

Dec 2025

Regimen

ALEC

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

alectinib - Treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer, according to specific criteria

Drugs Used:

alectinib

Quick Link(s):

Regimen Monograph

Dec 2025

Drug

abemaciclib

Other Name(s): Verzenio®

Quick Link(s):

Updated

Dec 2025

Regimen

ACAL

Cancer Type:

Hematologic

Intent: Palliative

Drugs Used:

acalabrutinib (Unfunded)

Quick Link(s):

Regimen Monograph

Dec 2025

Drug

acalabrutinib

Other Name(s): Calquence®

Quick Link(s):

Dec 2025

Regimen

ACAL

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), based on criteria

Drugs Used:

acalabrutinib

Quick Link(s):

Regimen Monograph

Dec 2025

Regimen

ASCI

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

asciminib - For the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, based on criteria

Drugs Used:

asciminib

Quick Link(s):

Regimen Monograph

Dec 2025

Regimen

AVD+NIVL

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative

Funding:

New Drug Funding Program

Nivolumab - In Combination with Chemotherapy for Previously Untreated Advanced Stage Hodgkin Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Dec 2025

Drug

larotrectinib

Other Name(s): Vitrakvi®

Quick Link(s):

Dec 2025

Drug

amivantamab

Other Name(s): Rybrevant®

Quick Link(s):

Dec 2025

Regimen

ANASRIBO

Cancer Type:

Breast

Intent: Adjuvant

Funding:

ODB - General Benefit

anastrozole

Drugs Used:

anastrozole,

ribociclib (Unfunded)

Quick Link(s):

Regimen Monograph

Dec 2025

Regimen

LETRRIBO

Cancer Type:

Breast

Intent: Adjuvant

Funding:

ODB - General Benefit

letrozole

Drugs Used:

letrozole,

ribociclib (Unfunded)